The cutaneous porphyrias

Dermatologic Clinics

Volumn 32, Issue 3, 2014, Pages 369-384

  Schulenburg Brand, Danja ^a   Katugampola, Ruwani ^a   Anstey, Alexander V ^b,c   Badminton, Michael N ^a,c  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Congenital erythropoietic porphyria; Cutaneous porphyria; Erythropoietic protoporphyria; Hereditary coproporphyria; Porphyria cutanea tarda; Variegate porphyria

Indexed keywords

CHLOROQUINE; PORPHYRIN; SUNSCREEN;

ACUTE INTERMITTENT PORPHYRIA; ADVERSE OUTCOME; CLINICAL FEATURE; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONSERVATIVE TREATMENT; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; ERYTHROPOIETIC PROTOPORPHYRIA; HUMAN; LABORATORY TEST; PATHOPHYSIOLOGY; PHLEBOTOMY; PHOTOSENSITIVITY DISORDER; PORPHYRIA CUTANEA TARDA; PREVALENCE; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SKIN DEFECT; SKIN FRAGILITY; STEM CELL TRANSPLANTATION; X CHROMOSOME DOMINANT DISORDER; ADVERSE EFFECTS; METABOLISM; PORPHYRIAS; PROTECTIVE CLOTHING; SKIN; SKIN DISEASES; SUNLIGHT;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PORPHYRIAS; PORPHYRINS; PROTECTIVE CLOTHING; SKIN; SKIN DISEASES; SUNLIGHT; SUNSCREENING AGENTS;

EID: 84901674261     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2014.03.001     Document Type: Review

References (111)

1. Puy H., Gouya L., Deybach J.C. Porphyrias. Lancet 2010, 375:924-937.
2. Schultz J.H. Ein Fall von Pemphigus leprosus complicirt durch Lepra visceralis. Inaugural Dissertation 1874, University of Griefswald.
3. Anderson T.M. Hydroea aestivale in two brothers complicated with the presence of haematoporphyrin in the urine. Br J Dermatol 1898, 10:1.
4. Stokvis B.J. Zur pathgenese der hamatoporphyrinurie. Z Klin Med 1895, 28:1-21.
5. Goldberg A. Historical perspective. Clin Dermatol 1998, 16:189-193.
6. Barnes H.D. Further South African cases of porphyrinuria. S Afr J Clin Sci 1951, 2:117-169.
7. Dean G. Porphyria variegata: a new disease. The porphyrias: a story of inheritance and environment 1971, 4-13. Pitman Medical, London.
8. Macalpine I., Hunter R., Rimington C. Porphyria in the royal houses of Stuart, Hanover, and Prussia. A follow-up study of George 3d's illness. Br Med J 1968, 1:7-18.
9. Hift R.J., Peters T.J., Meissner P.N. A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the 'Royal Malady'. J Clin Pathol 2012, 65:200-205.
10. Watson C.J., Schwartz S., Schulze W., et al. Studies of coproporphyrin III. Idiopathic coproporphyrinuria; a hitherto unrecognized form characterized by lack of symptoms in spite of the excretion of large amounts of coproporphyrin. J Clin Invest 1949, 28:465-468.
11. Berger H., Goldberg A. Hereditary coproporphyria. Br Med J 1955, 2:85-88.
12. Magnus I.A., Jarrett A., Pranker T.A., et al. Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 1961, 278:448-451.
13. Whatley S.D., Ducamp S., Gouya L., et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008, 83:408-414.
14. Lim H.W., Poh-Fitzpatrick M.B., Gigli I. Activation of the complement system in patients with porphyrias after irradiation in vivo. J Clin Invest 1984, 74:1961-1965.
15. Poh-Fitzpatrick M.B. Molecular and cellular mechanisms of porphyrin photosensitization. Photodermatol 1986, 3:148-157.
16. Poh-Fitzpatrick M.B. Porphyrin-sensitized cutaneous photosensitivity: pathogenesis and treatment. Clin Dermatol 1985, 3:41-82.
17. Brun A., Sandberg S. Mechanisms of photosensitivity in porphyric patients with special emphasis on erythropoietic protoporphyria. J Photochem Photobiol B 1991, 10:285-302.
18. Epstein J.H., Tuffanelli D.L., Epstein W.L. Cutaneous changes in the porphyrias. A microscopic study. Arch Dermatol 1973, 107:689-698.
19. Sneddon I.B. Congenital porphyria. Proc R Soc Med 1974, 67:593-594.
20. Bhutani L.K., Sood S.K., Das P.K., et al. Congenital erythropoietic porphyria. An autopsy report. Arch Dermatol 1974, 110:427-431.
21. Bhutani L.K., Deshpande S.G., Bedi T.R., et al. Cyclophosphamide and congenital erythropoietic porphyria. Photodermatol 1985, 2:394-398.
22. Jacobo A., Almeida H.L., Jorge V.M. Congenital erythropoietic porphyria in two siblings. Dermatol Online J 2005, 11:15.
23. Poh-Fitzpatrick M.B. A plasma pophyrin fluorescence marker for variegate porphyria. Arch Dermatol 1980, 116:543-547.
24. Piomelli S. A micromethod for free erythrocyte porphyrins: the FEP test. J Lab Clin Med 1973, 81:932-940.
25. Blake D., Poulos V. Diagnosis of porphyria- recommended methods for peripheral laboratories. Clin Biochem Rev 1992, 13:S1-S24.
26. Lockwood W.H., Poulos V., Rossi E., et al. Rapid procedure for fecal porphyrin assay. Clin Chem 1985, 31:1163-1167.
27. Lim C.K., Peters T.J. Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias. Clin Chim Acta 1984, 139:55-63.
28. Whatley S.D., Badminton M.N. Role of genetic testing in the management of patients with inherited porphyria and their families. Ann Clin Biochem 2013, 50:204-216.
29. Holme S.A., Anstey A.V., Badminton M.N., et al. Serum 25-hydroxyvitamin D in erythropoietic protoporphyria. Br J Dermatol 2008, 159:211-213.
30. Holme S.A., Anstey A.V., Finlay A.Y., et al. Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 2006, 155:574-581.
31. Lecha M., Puy H., Deybach J.C. Erythropoietic protoporphyria. Orphanet J Rare Dis 2009, 4:19.
32. Gouya L., Puy H., Robreau A.M., et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 2002, 30:27-28.
33. Gouya L., Martin-Schmitt C., Robreau A.M., et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet 2006, 78:2-14.
34. Elder G., Harper P., Badminton M., et al. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis 2013, 36:849-857.
35. Elder G.H., Gouya L., Whatley S.D., et al. The molecular genetics of erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2009, 55:118-126.
36. Balwani M., Doheny D., Bishop D.F., et al. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. Mol Med 2013, 19:26-35.
37. Holme S.A., Worwood M., Anstey A.V., et al. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 2007, 110:4108-4110.
38. Anstey A.V., Hift R.J. Liver disease in erythropoietic protoporphyria: insights and implications for management. Gut 2007, 56:1009-1018.
39. Mathews-Roth M.M., Pathak U.A., Fitzpatrick T.B., et al. Beta-carotene as an oral photoprotective agent in erythropoietic protoporphyria. JAMA 1974, 228:1004-1008.
40. Corbett M.F., Herxheimer A., Magnus I.A., et al. The long term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol 1977, 97:655-662.
41. Collins P., Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995, 132:956-963.
42. Sivaramakrishnan M., Woods J., Dawe R. Narrowband UVB phototherapy in erythropoietic protoporphyria: case series. Br J Dermatol 2014, in press.
43. Harms J., Lautenschlager S., Minder C.E., et al. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009, 60:306-307.
44. Milligan A., Graham-Brown R.A., Sarkany I., et al. Erythropoietic protoporphyria exacerbated by oral iron therapy. Br J Dermatol 1988, 119:63-66.
45. McGuire B.M., Bonkovsky H.L., Carithers R.L., et al. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 2005, 11:1590-1596.
46. Wahlin S., Srikanthan N., Hamre B., et al. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transpl 2008, 14:1340-1346.
47. Badminton M.N., Elder G.H., Whatley S.D. Clinical and molecular epidemiology of the porphyrias. Handbook of porphyrin science 2013, 119-150. World Scientific, New Jersey. G.C. Fereira, K.M. Kadish, K.M. Smith (Eds.).
48. Mendez M., Poblete-Gutierrez P., Garcia-Bravo M., et al. Molecular heterogeneity of familial porphyria cutanea tarda in Spain: characterization of 10 novel mutations in the UROD gene. Br J Dermatol 2007, 157:501-507.
49. Bygum A., Christiansen L., Petersen N.E., et al. Familial and sporadic porphyria cutanea tarda: clinical, biochemical and genetic features with emphasis on iron status. Acta Derm Venereol 2003, 83:115-120.
50. Aarsand A.K., Boman H., Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem 2009, 55:795-803.
51. Ajioka R.S., Phillips J.D., Weiss R.B., et al. Down-regulation of hepcidin in porphyria cutanea tarda. Blood 2008, 112:4723-4728.
52. Phillips J.D., Kushner J.P., Bergonia H.A., et al. Uroporphyria in the Cyp1a2-/- mouse. Blood Cells Mol Dis 2011, 47:249-254.
53. Phillips J.D., Bergonia H.A., Reilly C.A., et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A 2007, 104:5079-5084.
54. Jalil S., Grady J.J., Lee C., et al. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol 2010, 8:297-302.
55. Gisbert J.P., Garcia-Buey L., Pajares J.M., et al. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003, 39:620-627.
56. Munoz-Santos C., Guilabert A., Moreno N., et al. Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients. Medicine 2010, 89:69-74.
57. Bulaj Z.J., Phillips J.D., Ajioka R.S., et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000, 95:1565-1571.
58. Ellervik C., Birgens H., Tybjaerg-Hansen A., et al. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analysis including 66000 cases and 226000 controls. Hepatology 2007, 46:1071-1080.
59. Singal A.K., Kormos-Hallberg C., Lee C., et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol 2012, 10:1402-1409.
60. Valls V., Ena J., Enriquez-De-Salamanca R. Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. J Dermatol Sci 1994, 7:169-175.
61. Chinarro S., de Salamanca R.E., Perpina J., et al. Studies on in vitro formation of complexes between porphyrins and chloroquine. Biochem Int 1983, 6:565-568.
62. Rossmann-Ringdahl I., Olsson R. Porphyria cutanea tarda: effects and risk factors for hepatotoxicity from high-dose chloroquine treatment. Acta Derm Venereol 2007, 87:401-405.
63. Francanzani A.L., Taioli E., Sampietro M., et al. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol 2001, 35:498-503.
64. Hift R.J., Meissner D., Meissner P.N. A systematic study of the clinical and biochemical expression of variegate porphyria in a large South African family. Br J Dermatol 2004, 151:465-471.
65. Nordmann Y., Puy H., Da Silva V., et al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med 1997, 242:213-217.
66. Meissner P.N., Adams P., Kirsh R. Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. J Clin Invest 1993, 91:1436-1444.
67. Meyer U.A., Schuurmans M.M., Lindberg R.L. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 1998, 18:43-52.
68. Dowman J.K., Gunson B.K., Bramhall S., et al. Liver transplantation from donors with acute intermittent porphyria. Ann Intern Med 2011, 154:571-572.
69. Brodie M.J., Thompson G.G., Moore M.R., et al. Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood. Q J Med 1977, 46:229-241.
70. Hift R.J., Meissner P.N. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore) 2005, 84:48-60.
71. Mustajoki P., Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 1993, 153:2004-2008.
72. Millward L.M., Kelly P., King A., et al. Anxiety and depression in the acute porphyrias. J Inherit Metab Dis 2005, 28:1099-1107.
73. Pischik E., Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-grand) 2009, 55:72-83.
74. Deacon A.C., Elder G.H. ACP best practice no 165: front line tests for the investigation of suspected porphyria. J Clin Pathol 2001, 54:500-507.
75. Whatley S.D., Mason N.G., Woolf J.R., et al. Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem 2009, 55:1406-1414.
76. Stein P., Badminton M., Barth J., et al. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem 2013, 50:217-223.
77. Anderson K.E., Bloomer J.R., Bonkovsky H.L., et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005, 142:439-450.
78. Andersson C., Lithner F. Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med 1994, 236:169-175.
79. Andersson C., Wikberg A., Stegmayr B., et al. Renal symptomatology in patients with acute intermittent porphyria. A population-based study. J Intern Med 2000, 248:319-325.
80. Lithner F., Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand 1984, 215:271-274.
81. Andant C., Puy H., Bogard C., et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000, 32:933-939.
82. Astrin K.H., Warner C.A., Yoo H.W., et al. Regional assignment of the human uroporphyrinogen III synthase (UROS) gene to chromosome 10q25.2->q26.3. Hum Genet 1991, 87:18-22.
83. Aizencang G., Solis C., Bishop D.F., et al. Human uroporphyrinogen-III synthase: genomic organization, alternative promoters, and erythroid-specific expression. Genomics 2000, 70:223-231.
84. Ged C., Moreau-Gaudry F., Richard E., et al. Congenital erythropoietic porphyria: mutation update and correlations between genotype and phenotype. Cell Mol Biol (Noisy-le-grand) 2009, 55:53-60.
85. Katugampola R.P., Badminton M.N., Finlay A.Y., et al. Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. Br J Dermatol 2012, 167:901-913.
86. Anderson K., Sassa S., Bishop D., et al. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. The metabolic and molecular basis of inherited disease 2001, 2991-3062. McGraw-Hill Publishing, New York. 8th edition. C.R. Scriver, A.L. Beaudet, W.S. Sly (Eds.).
87. Verstraeten L., Van Regemorter N., Pardou A., et al. Biochemical diagnosis of a fatal case of Gunther's disease in a newborn with hydrops foetalis. Eur J Clin Chem Clin Biochem 1993, 31:121-128.
88. Daikha-Dahmane F., Dommergues M., Narcy F., et al. Congenital erythropoietic porphyria: prenatal diagnosis and autopsy findings in two sibling fetuses. Pediatr Dev Pathol 2001, 4:180-184.
89. Desnick R.J., Astrin K.H. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol 2002, 117:779-795.
90. De Verneuil H., Ged C., Moreau-Gaudry F. Congenital erythropoietic porphyria. The porphyrin handbook 2003, 43-63. Elsevier Science (USA), New York. 2nd edition. K.M. Kadish, K.M. Smith, R. Guilard (Eds.).
91. Anstey A. School in photodermatology: Smith-Lemli-Opitz syndrome. Photodermatol Photoimmunol Photomed 2006, 22:200-204.
92. Katugampola R.P., Anstey A.V., Finlay A.Y., et al. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. Br J Dermatol 2012, 167:888-900.
93. Kaufman L., Evans D., Stevens R., et al. Bone-marrow transplantation for congenital erythropoietic porphyria. Lancet 1991, 337:1510-1511.
94. Zix-Kieffer I., Langer B., Eyer D., et al. Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease). Bone Marrow Transplant 1996, 18:217-220.
95. Thomas C., Ged C., Nordmann Y., et al. Correction of congenital erythropoietic porphyria by bone marrow transplantation. J Pediatr 1996, 129:453-456.
96. Lagarde C., Hamel-Teillac D., De Prost Y., et al. Allogeneic bone marrow transplantation in congenital erythropoietic porphyria. Gunther's disease. Ann Dermatol Venereol 1998, 125:114-117.
97. Tezcan I., Xu W., Gurgey A., et al. Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation. Blood 1998, 92:4053-4058.
98. Shaw P.H., Mancini A.J., McConnell J.P., et al. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant 2001, 27:101-105.
99. Harada F.A., Shwayder T.A., Desnick R.J., et al. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol 2001, 45:279-282.
100. Dupuis-Girod S., Akkari V., Ged C., et al. Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Gunther disease). Eur J Pediatr 2005, 164:104-107.
101. Phillips J.D., Steensma D.P., Pulsipher M.A., et al. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood 2007, 109:2618-2621.
102. Taibjee S.M., Stevenson O.E., Abdullah A., et al. Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma. Br J Dermatol 2007, 156:567-571.
103. Faraci M., Morreale G., Boeri E., et al. Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria. Pediatr Transplant 2008, 12:117-120.
104. Lebreuilly-Sohyer I., Morice A., Acher A., et al. Congenital erythropoeietic porphyria treated by haematopoietic stem cell allograft. Ann Dermatol Venereol 2010, 137:635-639.
105. Hogeling M., Nakano T., Dvorak C.C., et al. Severe neonatal congenital erythropoietic porphyria. Pediatr Dermatol 2011, 28:416-420.
106. Singh S., Khanna N., Kumar L. Bone marrow transplantation improves symptoms of congenital erythropoietic porphyria even when done post puberty. Indian J Dermatol Venereol Leprol 2012, 78:108-111.
107. Fritsch C., Lang K., Bolsen K., et al. Congenital erythropoietic porphyria. Skin Pharmacol Appl Skin Physiol 1998, 11:347-357.
108. Korda V., Deybach J.C., Martasek P., et al. Homozygous variegate porphyria. Lancet 1984, 1:851.
109. Grandchamp B., Phung N., Nordmann Y. Homozygous case of hereditary coproporphyria. Lancet 1977, 2:1348-1349.
110. Poblete-Gutierrez P., Badeloe S., Wiederholt T., et al. Dual porphyrias revisited. Exp Dermatol 2006, 15:685-691.
111. Elder G.H. Porphyria cutanea tarda and related disorders. The porphyrin handbook 2003, 67-92. Elsevier Science (USA), San Diego (CA). 1st edition. K.M. Kadish, K.M. Smith, R. Guilard (Eds.).